The PCORnet Bariatric Study: Preliminary **Results from a Large PCORnet Demonstration Project**

NIH HCS Collaboratory and PCORnet Grand Rounds, August 17, 2018


Neely Williams, Mdiv; David Arterburn, MD MPH; Kathleen McTique, MD MPH; and Laura Rasmussen-Torvik, PhD MPH

on behalf of the PCORnet Bariatric Study Collaborative



A bit about the PCORnet Bariatric Study...

- Studying the three most commonly used weight-loss procedures in the US
 Adjustable Gastric Band Castric Band Cast
 - Adjustable gastric band (AGB) lap band or band
 - Roux-en-Y gastric bypass (RYGB) bypass
 - Sleeve gastrectomy (SG) sleeve



Adapted from an illustration by Walter Pories, MD, FACS

We are looking at how each procedure compares to the other two for:

- Weight loss and regain; Improvement in diabetes risk; Adverse events over a 1, 3, and 5 year interim
- Why is this topic important?
 - Use of bariatric surgery has expanded considerably
 - Sleeve gastrectomy procedure has been used increasingly over past decade – despite a lack of data comparing its effectiveness to other procedures



A bit about me....

- As stated I am, Neely Williams, one of the co-PI of this study
- Patient/Non-Scientist
- I had Bariatric Surgery in 2011 7 years ago
- I am a widow, mother and great grandmother
- I also work as a community engagement strategist, and minister
- My experiences led me to PCORnet a Network dedicated to placing patients central in the research process



My road map to becoming a Patient PI in the bariatric study

- As a PI, I worked to develop <u>solutions</u> and contributed to <u>decision</u> <u>making</u>
- I am a minister, a community advocate, and a community organizer
 - Case management for diverse populations
 - Coalition building for different initiatives
- I have served in numerous capacities in the Greater Nashville Community
- I served on the PCORnet Obesity Task Force (2014)
 - Task Force members: patients, surgeons, researchers



Major Successes (January 2016 – Aug 2018)

- 7 Common Data Model (CDM) queries successfully executed
 - Study Specific Data Characterization (n=2)
 - Scientific Queries
 - <u>Weight loss (n=2)</u>, individual-level & distributed

- 41 data contributing sites from 11 CDRNs

• <u>Diabetes risk (n=2)</u>, individual-level & distributed

— 34 data contributing sites from 11 CDRNs

- <u>Adverse Events (n=1)</u>, individual level
 - 10 data contributing sites from 5 CDRNs



Major Successes (January 2016 – Aug 2018)

- Major dissemination activities:
 - Published papers:
 - Cohort Description, JMIR Research Protocols
 - Adolescent weight loss, Surgery for Obesity & Related Diseases
 - Papers in progress:
 - Adult weight loss, revised & resubmitted twice, Annals of Internal Medicine
 - Comparison of weight loss/regain in individual-level vs. distributed queries, in review, Clinical Epidemiology
 - 3 other manuscripts in production
 - 5 abstracts accepted by three conferences
- Tremendous amount of work to collect & analyze data in ~18 months
 - Coordinating Center work: programming, beta-testing & distributing queries
 - Site teams of data collection: running queries, troubleshooting data
 - Scientific Core team: leading data cleaning & analyses



46,510 adults from 41 health systems

Procedure distribution

- 24,982 RYGB (53%)
- 18,961 SG (41%)
- 2,567 AGB (6%)



46,510 adults from 41 health systems

Procedure distribution

- 24,982 RYGB (53%)
- 18,961 SG (41%)
- 2,567 AGB (6%)

Mean age 46; 80% female; 21% Hispanic; 21% African American



46,510 adults from 41 health systems

Procedure distribution

- 24,982 RYGB (53%)
- 18,961 SG (41%)
- 2,567 AGB (6%)

Mean age 46; 80% female; 21% Hispanic; 21% African American

Mean BMI: 49 kg/m² with 38% BMI 50+ kg/m²



- 46,510 adults from 41 health systems
- Procedure distribution
 - 24,982 RYGB (53%)
 - 18,961 SG (41%)
 - 2,567 AGB (6%)
- Mean age 46; 80% female; 21% Hispanic; 21% African American
- Mean BMI: 49 kg/m² with 38% BMI 50+ kg/m²
- 60% HTN; 49% Dyslipidemia; 49% OSA; 40% GERD;
 37% T2DM; 30% Depression; 21% Anxiety



46,510 adults from 41 health systems

- Procedure distribution
 - 24,982 RYGB (53%)
 - 18,961 SG (41%)
 - 2,567 AGB (6%)

Mean age 46; 80% female; 21% Hispanic; 21% African American

Mean BMI: 49 kg/m² with 38% BMI 50+ kg/m²

60% HTN; 49% Dyslipidemia; 49% OSA; 40% GERD;
 37% T2DM; 30% Depression; 21% Anxiety

RYGB patients had higher BMI & more comorbidity pcornet

Availability of follow-up weight measures, adults


	1-year	3-year	5-year
		N (% of eligible)	
All procedures	44,978 (84%)	20,783 (68%)	7,159 (69%)




Availability of follow-up weight measures, adults

	1-year	3-year	5-year	
	N (% of eligible)			
All procedures	44,978	20,783	7,159	
	(84%)	(68%)	(69%)	
RYGB	24,061	12,429	5,257	
	(86%)	(67%)	(67%)	
Sleeve	18,550	6,847	1,293	
	(84%)	(73%)	(76%)	
AGB	2,367	1,507	609	
	(76%)	(60%)	(55%)	







pcornet[®]







pcornet[®]






Subgroups who lost less weight with bariatric surgery

- Older patients (>65 years)
- Patients with diabetes
- African American & Hispanic patients
- Patients with pre-operative BMI <50 kg/m²
- Differences were generally <3% TWL</p>




A similar weight loss pattern was seen in 544 adolescents from 27 health systems, but less follow-up data



Inge T, et al for the PBS Collaborative. Surg Obes Relat Dis. 2018 (in press)

A similar weight loss pattern was seen in 544 adolescents from 27 health systems, but less follow-up data



Inge T, et al for the PBS Collaborative. Surg Obes Relat Dis. 2018 (in press)

Aim 2: Diabetes Outcomes

- Primary Outcome:
 - Diabetes Remission: defined as HbA1c <6.5% after 6 months without any prescription order for a diabetes medication
- Secondary Outcomes:
 - DM Relapse: defined as HbA1c ≥6.5% or the occurrence of any prescription order for a diabetes medication



Among 10,019 PBS patients with active diabetes...

50% of patients had a HbA1c <7; 22% had HbA1c ≥8






Among 10,019 PBS patients with active diabetes...

- 50% of patients had a HbA1c <7;
 22% had HbA1c ≥8
- On average, patients used 1.7
 DM prescription medications
 - 0 DM meds: 19%
 - 1 DM med: 22%
 - >3 DM meds: 20%
- Most common DM drugs: Biguanides (e.g., metformin; 65%), Insulins (48%) & Sulfonylureas (32%)







Cumulative incidence of DM remission



Cumulative incidence of DM remission



Cumulative incidence of DM remission



Adjusted HRs for diabetes remission

Diabetes	Adjusted HR (95% CI)	P-Value	
Remission	Aujusteu fik (9570 čij		
RYGB vs SG	1.10 (1.04, 1.16)	0.007	
RYGB vs AGB	2.19 (1.89, 2.53)	<0.0001	
SG vs AGB	1.85 (1.53, 2.25)	<0.0001	

Rate of remission was:

- 10% higher for RYGB vs. SG patients
- ~twice as high for RYGB vs. AGB patients



Adjusted HRs for diabetes remission


Diabetes	Adjusted HR (95% CI)	P-Value	
Remission	Aujusteu fik (9570 čij		
RYGB vs SG	1.10 (1.04, 1.16)	0.007	
RYGB vs AGB	2.19 (1.89, 2.53)	<0.0001	
SG vs AGB	1.85 (1.53, 2.25)	<0.0001	

Rate of remission was:


ocornet

- 10% higher for RYGB vs. SG patients
- ~twice as high for RYGB vs. AGB patients
- ~twice as high for SG vs. AGB patients


Cumulative incidence of diabetes relapse



Cumulative incidence of diabetes relapse



Cumulative incidence of diabetes relapse



Preliminary results. Do not cite without permission from authors.

Subgroups with lower rates of remission

Patients who were prescribed insulin

 Those who had RYGB had higher rates of DM remission than those who had SG

Patients with poorly controlled diabetes (HbA1c > 7)

 Those who had RYGB had higher rates of DM remission than those who had SG

Racial/ethnic background & starting BMI (<50 vs <u>></u>50) did not impact DM remission rates



Aim 3 – Adverse Events

Data collection restricted to those health systems that had existing linkages to insurance claims and death data or sites with sufficient samples and ability to link to claims and death data

34,089 adults from 10 sites in 5 CDRNs

- 1, 3, and 5-year Adverse Event Outcomes:
 - Reoperation
 - Reoperation with endoscopy
 - Rehospitalization
 - Mortality

30-day rate of Major Adverse Events



Adjusted 5-year Adverse Events

	SG (n=15504)	RYGB (n=18056)	AGB (n=1154)
Any reoperation	18%	20%	28%
Any reoperation or endoscopy	23%	30%	31%
Rehospitalization (all cause)	33%	38%	42%
Death (all cause)	0.84%	0.89%	1.08%



Adjusted Hazard Ratios Comparisons Between Procedures

	SG vs RYGB	AGB vs RYGB	AGB vs. SG
30-day Major Adverse Event	0.74*	0.46*	0.62*
Reoperation	0.89*	1.45*	1.62*
Reoperation or endoscopy	0.72*	1.02	1.42*
Rehospitalization (all cause)	0.82*	1.14*	1.39*
Mortality (all cause)	0.94	1.22	1.29
		*0.00	

*P<0.05



Limitations

- Observational data; confounding that may have persisted despite covariate & propensity score adjustment
- Missing BMI, HbA1c data may introduce bias
 - Sensitivity analyses suggest missing data were unlikely to change the interpretation of our main results
- Comorbid health conditions identified from ICD-9 may underestimate prevalence, can be inaccurately coded, & do not account for severity
- GB procedure under-represented as often carried out in small ambulatory surgical centers
- DM medication use is estimated from prescribing data, not dispensing, & does not account for adherence
- Within a calendar year, unable to differentiate loss to follow-up due to administrative reasons vs. health care utilization



How did stakeholders contribute to the *research idea*?

PCORnet Obesity Task Force (2014) – Generated obesity research topic ideas. Ideas were prioritized, resulting in a PCORI funding announcement for two topics (weight loss surgery; effects of antibiotics on weight in children)

O At PBS kick-off meeting, requested two major changes to science:

- Do <u>three pair-wise comparisons of bariatric procedures</u>, as opposed to two pair-wise comparisons
- Interview <u>bariatric surgeons as part of qualitative aim</u> not just conduct patient focus groups

These activities were carried out, with <u>stakeholder input on data</u> <u>collection</u> and <u>interpretation</u>.



How did our stakeholders help us *develop* and execute our scientific aims?

Reviewed plans to identify cohort.

- Includes reviewing <u>diabetes medication lists</u>, <u>bariatric surgery</u> procedure codes.
- Using the same process as investigators, prioritized our HTE analyses. Final rankings were decided by investigators and stakeholders.
- Actively participated in <u>development of focus group</u> and <u>surgeon</u> <u>interview templates.</u>



My perspective of Lessons Learned as a Patient PI

- How to Create a collaborative environment where all stakeholders are empowered to share their prospective and expertise - including patients/non-scientists.
- Enhanced understanding and appreciation for the LIVED EXPERIENCE in the research process.
- Intentional planning remember the issues and needs of patients are different than researchers who are funded to carryout this & similar work. Patients need:
 - Funding for dissemination travel
 - Increased time to understand scientific documents
 - Setting time aside to review these w/ partners is invaluable
 - Capacity to securely receive study sensitive data (when it is part of project's output)

Increased training for patient/non-scientist in the overall research process




Participating in a PCORI demonstration project: A network lead PI perspective

Laura Rasmussen-Torvik, PhD, MPH, FAHA Assistant Professor Department of Preventive Medicine Northwestern University Feinberg School of Medicine

CAPriCORN Network Lead Investigator and Northwestern University Site Investigator for the Bariatric Surgery Demonstration Project





Critical EARLY education of a (network lead) PI


Solution Working with the PCORI CDM

The collaborative and administrative nature of a CDRN project





Data sources—<u>bariatric surgery</u> research



Network lead PI responsibilities


- IRB approval at all node sites
- Budgeting at all node sites
- Monitoring query completion at all node sites
- Stakeholder identification
- Authorship for the network at all node sites
 - A well-organized central project team is required for all of the above to succeed

Participation on research team

design, analysis and interpretation decisions



Understanding node site data



The elephant in uremia: Oxidant stress as a unifying concept of cardiovascular disease in uremia Jonathan Himmelfarb, Peter Stenvinkel, T. Alp Ikizler, Raymond M. Hakim Kidney International Volume 62, Issue 5, Pages 1524-1538 (November 2002) DOI: 10.1046/j.1523-1755.2002.00600.x



pcornet

Terms and Conditions

Critical contributors from each node (*data* contributing) site

Clinical expert with awareness of local practice patterns

Informatics expert with understanding of conversion of EHR to CDM

Topical experts in various aspects of bariatric surgery research



Authorship

Pls, Scientific Core

PCORnet CC


Stakeholders

😳 Node site

Clinical

ocornet

- Informatics
- Topical experts
- Requires central organization
 - Early opportunity for feedback on results
 - Multiple rounds of review before dissemination to a large group
 - CDRN-level contact with contributors
 - PCORI guidelines provide framework



Questions?

For more information -

- pcornetbariatricstudy.org
- <u>https://clinicaltrials.gov/ct2/show/NCT02741674</u>
- A description of the study cohort
 - The National Patient-Centered Clinical Research Network (PCORnet) Bariatric Study Cohort: Rationale, Methods, and Baseline Characteristics. <u>JMIR Research Protocols</u>. 2017 Dec 5;6(12):e222.
- Results: Weight loss and regain in adolescents
 - PCORnet Bariatric Study Collaborative. Comparative effectiveness of bariatric procedures among adolescents: the PCORnet bariatric study. <u>Surg Obes Relat Dis. 2018 Apr 17</u>. [Epub ahead of print]

